SCHEMBL1901337

SCHEMBL1901337

Nc1ccc2nc(-c3ccccc3)cc(C(=O)O)c2c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPRS1 P07814 1/20 0.77
KDM4E B2RXH2 2/20 0.69
LMNA P02545 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
PDE10A Q9Y233 1/20 0.69
HSD17B10 Q99714 3/20 0.69
ALDH1A1 P00352 3/20 0.69
DHODH Q02127 7/20 0.66
HIF1A Q16665 2/20 0.65
TP53 P04637 1/20 0.65
CYP1A2 P05177 1/20 0.65
CYP2C19 P33261 1/20 0.65
POLB P06746 1/20 0.58
PTGES O14684 1/20 0.58
ALOX5 P09917 1/20 0.58
CYP2C9 P11712 1/20 0.58
HPGD P15428 1/20 0.58
CASP7 P55210 1/20 0.58
RXFP1 Q9HBX9 1/20 0.58
AKR1C3 P42330 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL117388 0.87 EPRS1 (1.00) EPRS1KDM4ELMNAHSD17B10ALDH1A1
SCHEMBL16921273 0.85 DHODH (0.80) EPRS1KDM4ELMNASMN1; SMN2PDE10A
SCHEMBL1897678 0.83 POLB (0.73) EPRS1KDM4ELMNASMN1; SMN2PDE10A
SCHEMBL5534047 0.82 KDM4E (0.75) KDM4ELMNASMN1; SMN2PDE10AALDH1A1
Cinchophen SCHEMBL29376617 0.82 KDM4E (1.00) KDM4ELMNASMN1; SMN2PDE10AHSD17B10
Cinchophen SCHEMBL25519 0.82 KDM4E (1.00) KDM4ELMNASMN1; SMN2PDE10AHSD17B10
Cinchophen SCHEMBL7588217 0.82 KDM4E (1.00) KDM4ELMNASMN1; SMN2PDE10AHSD17B10
SCHEMBL1898810 0.82 KDM4E (1.00) KDM4ELMNASMN1; SMN2PDE10AHSD17B10
SCHEMBL1901465 0.82 KDM4E (0.69) KDM4ELMNASMN1; SMN2PDE10AHSD17B10
SCHEMBL1903454 0.82 DHODH (0.94) KDM4ELMNASMN1; SMN2PDE10AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2325181-B1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2017-03-29 EP disclosed
CN-102099352-B STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient PHARMA IP GENERAL INC ASS 2014-02-26 CN disclosed
US-8466290-B2 STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2013-06-18 US disclosed
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2011-07-14 US disclosed
CN-102099352-A STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient PHARMA IP GENERAL INC ASS 2011-06-15 CN disclosed
EP-2325181-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT Pharma Ip General Incorporated Association (JP) 2011-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT STAT3, STAT4, STAT5B EPRS1 2555/4885KDM4E 532/4885LMNA 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.